Amedisys - AMED Stock Forecast, Price & News

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Amedisys Price Performance

Amedisys stock opened at $122.36 on Monday. The business has a 50 day simple moving average of $118.97 and a 200-day simple moving average of $134.30. The stock has a market capitalization of $3.97 billion, a PE ratio of 28.52, a price-to-earnings-growth ratio of 2.95 and a beta of 0.95. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.92 and a quick ratio of 0.92. Amedisys has a 12 month low of $101.61 and a 12 month high of $188.88.

Amedisys (NASDAQ:AMED - Get Rating) last released its quarterly earnings data on Wednesday, July 27th. The health services provider reported $1.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.24. The firm had revenue of $557.89 million during the quarter, compared to analysts' expectations of $583.12 million. Amedisys had a return on equity of 17.81% and a net margin of 6.33%. Amedisys's revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.69 earnings per share. Equities analysts predict that Amedisys will post 5.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on AMED shares. Deutsche Bank Aktiengesellschaft dropped their target price on Amedisys from $210.00 to $175.00 and set a "buy" rating for the company in a research report on Tuesday, June 21st. Raymond James lowered their price objective on Amedisys from $200.00 to $180.00 in a research report on Friday, April 29th. Jefferies Financial Group reissued a "buy" rating and set a $200.00 price objective on shares of Amedisys in a research report on Tuesday, June 28th. Truist Financial lowered their price objective on Amedisys from $175.00 to $150.00 and set a "buy" rating for the company in a research report on Thursday, July 14th. Finally, Bank of America downgraded Amedisys from a "neutral" rating to an "underperform" rating and lowered their price objective for the stock from $145.00 to $102.00 in a research report on Tuesday, June 21st. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $158.53.

Insiders Place Their Bets

In other Amedisys news, insider Denise M. Bohnert sold 557 shares of the stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $115.00, for a total value of $64,055.00. Following the completion of the transaction, the insider now owns 11,850 shares in the company, valued at $1,362,750. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.10% of the stock is currently owned by company insiders.